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INTRODUCTION
Down syndrome (DS) has an incidence of one per 700 live
births and is caused by complete or partial triplication of hu-
man chromosome 21 (1). Nondisjunction during meiosis may
be responsible for the various phenotypes of DS, and -70% of
nondisjunction errors have been found to occur during meio-
sis I and the other 30% during meiosis II (2, 3). DS is char-
acterized clinically by abnormal facial and skeletal features (4),
mental retardation (5), precocious dementia (6) and congen-
ital heart disease (7, 8). 
Recently, genomic approach for DS has been performed
using various clinical samples. However, the gene expression
study using DS fetus has some limitation, especially for amni-
otic fluid (AF) cells. AF is commonly used for prenatal diag-
nosis in obstetrics and gynecology, which includes various
tissue of origin for fetal DS. Our genomic approach for AF
cells of DS may provide basic information for understanding
of the development of DS fetus.
The differential expression of genes located on the extra copy
of chromosome 21 has been assumed to be responsible for the
phenotypic abnormalities of DS, but this gene dosage hypoth-
esis has not been fully assessed on a genome-wide basis. The
expression patterns of genes related to phenotypic abnormali-
ties of DS may provide insights into their potential roles in DS.
For example, DSCR-1 gene on chromosome 21 is developmen-
tal regulator gene and is involved in neurogenesis. Moreover,
its overexpression may contribute to brain abnormalities (9).
SIM2 gene is a transcriptional regulator that operates as a
important determinant of the central nervous system and is
a candidate gene for the pathogenesis of mental retardation
in DS (10). The overexpression of S100beta in the AF of DS
fetuses may be related to the appearance of Alzheimer-type
neuropathological changes in DS (11).
We used the DNA microarray technique (12) using AF
cells in DS to investigate the pathogenesis of this syndrome,
and also identify biological markers of DS in based on a high-
throughput method. Although it is not fully clear how AF
cell can represent the phenotype of this syndrome, the differ-
ential gene expression by extra copy of chromosome 21 would
be expected even in AF cells, regardless of the tissue of origin
(13). Our microarray analysis determined the expressions level
of 102 genes potentially important in DS from cultured AF
cells at 16-18 weeks of gestation.
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Gene Expression Analysis of Cultured Amniotic Fluid Cell with Down
Syndrome by DNA Microarray
Complete or partial triplication of human chromosome 21 results in Down syndrome
(DS). To analyze differential gene expressions in amniotic fluid (AF) cells of DS, we
used a DNA microarray system to analyze 102 genes, which included 24 genes on
chromosome 21, 28 genes related to the function of brain and muscle, 36 genes
related to apoptosis, 4 genes related to extracellular matrix, 8 genes related to other
molecular function and 2 house-keeping genes. AF cells were collected from 12 preg-
nancies at 16-18 weeks of gestation in DS (n=6) and normal (n=6) subjects. Our DNA
microarray experiments showed that the expressions of 11 genes were altered by
at least 2-folds in DS, as follows. Ten genes, COL6A1, CASP5, AKT2, JUN, PYGM,
BNIP1, OSF-2, PRSS7, COL3A1, and MBLL were down-regulated and GSTT1 was
only up-regulated. The differential expressions of GSTT1 and COL3A1 were further
confirmed by semi-quantitative RT-PCR for each sample. The gene dosage hypoth-
esis on chromosome 21 may explain the neurological and other symptoms of DS.
However, our results showed that only two genes (COL6A1 and PRSS7), among
24 genes on chromosome 21, were down-regulated in the AF cells of DS. Our data
may provide the basis for a more systematic identification of biological markers of
fetal DS, thus leading to an improved understanding of pathogenesis for fetal DS.
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MATERIALS AND METHODS
Cell culture and cytogenetic analysis
AF samples of DS and normal subjects were collected from
women undergoing routine amniocentesis for genetic testing.
From July 2001 to November 2002, 12 women with preg-
nancies of DS (n=6) and normal (n=6) subjects, at the CHA
General Hospital, College of Medicine, Pochon CHA Univer-
sity (Seoul, Korea), gave informed consent for the use of their
AF cells, which only included for this study. Pochon CHA
college of Medicine’s Institutional Reviewed Board approved
this study for human subjects. After centrifugation of AF (10
mL) at 1,800 rpm for 10 min, the pellet of AF 0.5 mL was
added to 2 mL of CHANG media (IRVINE SCIENTIFIC,
Santa Ana, CA, U.S.A.) in a culture dish. AF cells were grown
in the tissue culture flask under 5% CO2 at 37℃in CHANG
media for DNA microarray analysis. Cytogenetic analysis for
determination of DS was performed on metaphase spreads of
cultured AF cells by standard method. 
RNA extraction and fluorescent cDNA probes labeling
AF cells were obtained from patients at 16-18 weeks ges-
tation. DS (n=6) and normal (n=6) subjects, respectively, total
RNA was extracted from normal and DS AF cells (at 80-90%
confluency) using RNeasy minikit (QIAGEN, Valencia, CA,
U.S.A.). Total RNA isolated from every subject was quanti-
tated. The purity of total RNA was confirmed by spectropho-
tometer and agarose gel electrophoresis. Each 30  g of total
RNA from DS (n=6) and normal (n=6) subjects was pooled,
and labeled with either Cy3UTP or Cy5UTP (NEN Life Sci-
ence Products, Boston, MA, U.S.A.) during reverse transcrip-
tion (RT). The RT was performed using 2  g/ L oligo dT
(Invitrogen, Carlsbad, CA, U.S.A), 0.1 M DTT, 200  / L
superscript enzyme, 5× first strand buffer (Gibco BRL, Cergy
Pontoise, France), 25 mM dATP, dGTP, dCTP, 15 mM dTTP
(Amersharm, Pharmacia, Piscataway, NJ, U.S.A.), 1 mM Cy3
or Cy5 labeled dUTP (NEN). Reaction mixture was incubat-
ed at 65℃ for 10 min for denaturation, 42℃ for 2 hr for RT.
After first strand cDNA synthesis the RNA was degraded by
Gene symbol Accession No. Gene symbol Accession No. Gene symbol Accession No.
ACTA2 NM_001613 COL3A1 X14420 PDPK1 AC005591
ACTB BC002409 COL5A2 NM_000393 PFKL NM_001002021
ACTG2 X16940 COL6A1 X99135 PGAM1 J04173
ADAM17 U86755 COL6A3 X52022 PGAM2 M55674
ADCY2 L21993 COL8A1 X57527 PKM2 NM_002654
ADCY8 NM_001115 CRADD NM_003805 PLAT M15518
AKT1 NM_005163 CRYAA NM_000394 PPP13A X78578
AKT2 M77198 CTGF NM_001901 PRG1 J03223
APEG1 NM_005976 CXADR AI557255 PRSS11 D87258
ATP5A1 AW161540 DPP4 M74777 PRSS7 U09860
BACH1 AI830904 EI24 NM_004879 PTE1 X86032
BAD NM_004322 GABRG3 S82769 PTEN U93051
BAG1 NM_004323 GAD1 NM_000817 PWP2H AB001517
BAI2 AB005298 GAPDH NM_002046 PYGB J03544
BAI3 AB005299 GBX1 L11239 PYGM U94777
BAK1 AI741331 GRIK1 NM_000830 SFN NM_006142
BCL6 NM_001706 GSTT1 NM_000853 SFRS25 AI937268
BDNF X60201 HRMT1L1 NM_001535 SLC25A4 J04982
BID NM_001196 IFNAR1 X60459 SUMO3 NM_006936
BIK NM_001197 IGFBP4 U20982 SYNJ1 AB020717
BIRC3 NM_001165 IL10RB NM_000628 TFF1 X52003
BIRC5 U75285 JUN NM_002228 TFF2 NM_005423
BNIP1 U15172 KCNJ6 AA056665 TGFB2 Y00083
C5orf13 NM_004772 LITAF NM_004862 TMEM1 U61500
CAPZA1 U56637 MBLL AF061261 TNFSF10 NM_003810
CASP1 U13697 MX2 M33883 TP53 U94788
CASP3 U13738 MYH3 X13100 TP53BP2 NM_005426
CASP4 U25804 MYH7 M57965 TRAF2 NM_021138
CASP5 X94993 MYH9 Z82215 TRAF5 U69108
CASP7 NM_001227 NCAM21 U75330 TRPM2 AB001535
CASP8 NM_001228 NOS2A U31511 TTC3 D84294
CFL2 AL117457 OSF-2 NM_006475 U2AF1 M96982
CHRNB1 AW157173 PCDH7 AB006757 UBE2G2 NM_003343
COL18A1 AF018081 PCNA NM_002592 WRB NM_004627
Table 1. List of 102 genes on cDNA microarray with accession number84 I.-H. Chung, S.-H. Lee, K.-W. Lee, et al.
adding 15  L of 0.1 N NaOH and incubating at 65℃ for
30 min. 15  L of 0.1 N HCl was added for neutralization.
cDNA microarray analysis
We used cDNA chip which contained 102 genes located
on chromosome 21 (24 genes), genes expressed in brain (11
genes) or muscle (17 genes) and apoptosis related genes (36
genes), extracellular matrix (ECM) related genes (4 genes),
genes related to other molecular function (8 genes) and house-
keeping genes (2 genes). The list of genes with accession num-
ber was shown in Table 1, and functional category of total
genes analyzed by GeneSpring was shown Fig. 1A (Silicon
Genetics, Redwood City, CA, U.S.A.). PCR-ampilfied EST
of 102 genes were fabricated by duplicate on Corning glass
slide (Disgene, Seoul, Korea).
Fluorescent cDNA probes were dried after ethanol prepa-
ration, and resuspended in 20  L hybridization buffer of TE
(pH 8.0), 20× SSC and 10% SDS. The labeled cDNA was
heated at 100℃for 2 min then incubated at 37℃for 30 min.
Reaction mixture was dropped on the slide and covered by
a cover slip. The slide was assembled with a hybridization
chamber and hybridized for 16 hr at 65℃.
Data analysis
The slide was dried by centrifugation and then scanned
on ScanArray 4000XL (Packard Bioscience, Billerica, MA,
U.S.A.). After registration of Cy3 and Cy5 images, the uni-
fied image was quantified using ImaGeneTM ver 4.0 (BioDis-
covery, Inc., Los Angeles, CA, U.S.A.). Normalization was
performed from the quantified data by mean intensity of 102
genes on the slide (Global normalization). 
Semiquantitative RT-PCR analysis
For confirmation of gene expression level, semi-quantitative
RT-PCR was performed using OneStep RT-PCR kit (QIA-
GEN, Inc., Valencia, CA, U.S.A.) according to the manufac-
turer’s direction. For RT-PCR, 100 ng of total RNA was re-
verse transcribed at 50℃ for 30 min in 50  L final volume
by 2  L of OneStep RT-PCR enzyme mix. Each gene specific
primers were added in first strand synthesis step. The RT-PCR
products were subjected to electrophoresis on 1% agarose gel.
Differentially expressed genes were detected using the follow-
ing primer pairs; COL3A1 sense, 5′ -gtggacagattctagtgctgag-
3′ , antisense, 5′ -ataggtagtctcacagccttgc-3′ , GSTT1 sense, 5′ -
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Fig. 2. Histogram and scatter plot by DNA microarray experiment.
(A) This histogram shows the distribution of gene expression ratios
between normal and DS subjects. One gene (GSTT1) was up-reg-
ulated and ten genes were down-regulated in DS. The horizontal
axis refers to the expression ratio, and vertical axis indicates num-
ber of genes. (B) Each spot represents a single gene. Genes were
expressed the same level in two samples fall along 45 °angle line.
Black spots were expressed over 2-folds but empty spots are ex-
pressed less than 2-folds.
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Fig. 1. The ontology of genes on the chip. (A) One hundred two
genes were classified into functional subgroups using Simplified
ontology in GeneSpring (Silicon Genetics, Redwood City, CA,
U.S.A.). (B) The PCR amplicons of human cDNA clones were spot-
ted in 4 blocks using a 4-pin print head, and all of genes spotted in
duplicate. The similar result has shown by the repeated experiments.
GAPDH and  -actin were spotted in last row of each blocks.Microarray Analysis of Cultured Amniotic Fluid Cell in Down Syndrome 85
tgactactggtaccctcaggac-3′ , antisense, 5′ -aggtcagctaaggagatgt-
gag-3′ , and GAPDH sense, 5′ -accacagtccatgccatcac-3′ , anti-
sense, 5′ -tccaccaccctgttgctgta-3′ .
RESULTS
Analysis of the gene expression profiles by DNA microarray
Microarray is powerful tool for analyzing expression profile
and identifying bio-marker in clinical samples. In our microarray
experiment, the RNA samples of the normal (n=6) and DS
(n=6) subjects were pooled to reduce the effect of individual
variations. Hybridization spots were quantified and normal-
ized using ImaGeneTM ver 4.0 software (BioDiscovery, Inc.,
Marina del Rey, CA, U.S.A.). To normalize the intensity levels of
genes on the chip, we compared the Cy3:Cy5 intensity ratios
of all spots on the array (Global normalization). GAPDH and
-actin, the housekeeping genes, were used as controls and
the signal intensity of these genes was represented the almost
same in Cy3 and Cy5 (Fig. 1B). The overall hybridization
signals obtained by using cDNA probe of normal and DS
subjects were similar (<2-folds). Eleven genes in DS showed
the differences of 2-folds or more (Fig. 2).
Differentially expressed genes in DS samples
Differentially expressed genes are represented by a pair
mean ratio (Log2Test Mean/Control Mean) of signal intensity.
The overexpression of gene was defined as a pair mean ratio
of >1.0. Eleven genes were differentially expressed in DS, as
summarized in Table 2. Only one gene, GSTT1, was up-reg-
ulated (1/102, 1%) and 10 genes were down-regulated in DS
(10/102, 10%); OSF-2, PYGM, AKT2, JUN, BNIP1, COL-
3A1, COL6A1, CSAP5, PRSS7 and MBLL (Fig. 2). These
genes fell into the following groups: 1) Cell communication;
OSF-2 and PYGM, 2) Signal transduction; AKT2, JUN and
BNIP1, 3) Apoptosis; CSAP5, 4) Enzyme; PRSS7 and GSTT1.
The functional categorization differentially expressed genes
were classified using GeneSpring (ver 6 Silicon Genetics, Red-
wood, CA, U.S.A.) and summarized in Table 2.
Semi-quantitative RT-PCR of COL3A1 and GSTT1
We confirmed the microarray results to validate these differ-
entially expressed genes in DS and normal samples by semi-
quantitative RT-PCR, and the matched results were observed
(data not shown). We selected two genes; one up-regulated
gene (GSTT1) and one down-regulated gene (COL3A1), for
analysis of every subject, and the semi-quantitative RT-PCR
results are shown in Fig. 3. GSTT1 was highly expressed in
50% of DS subjects (3/6), but in only one of normal subjects
(1/6, 17%). The expression of COL3A1 was down-regulated
in the DS subjects (5/6, 83%), but not in the normal subjects
(0/6, 0%).
Function Gene symbol Gene name Cytogenetic
band
Pair
mean ratio
DS
mean
Normal
mean
Cell communication OSF-2 osteoblast specific factor 2 13q13.3 -2.6572 0.5844 3.2416
PYGM phosphorylase, glycogen; muscle (McArdle 11q12-q13.2 -1.8919 -3.5318 -1.6399
syndrome, glycogen storage disease type V)
Signal transduction AKT2 v-murine thymoma viral oncogene homolog 2 19q13.1-13.2 -1.5693 -2.8539 -1.2846
JUN Jun activation domain binding protein 1p32-p31 -1.8848 -2.5215 -0.6367
Apoptosis regulator BNIP1 BCL2/adenovirus E1B 19kD-interacting protein 1 5q33-q34 -2.4471 0.6206 3.0677
CASP5 caspase 5, apoptosis-related cysteine protease 11q22.2-22.3 -1.2177 -3.5112 -2.2935
Enzyme PRSS7 protease, serine, 7 (enterokinase) 21q21.1 -3.0414 -5.0273 -.9858
GSTT1 glutathione S-transferase theta 1 22q11.23 6.4404 -0.8874 -7.3278
Extracellular matrix COL6A1 collagen, type VI, alpha 1 21q22.3 -1.0268 1.9419 2.9687
COL3A1 collagen, type III, alpha 1 2q31 -3.1432 -1.5276 1.6157
Neucleic acid binding MBLL Homo sapiens muscleblind-like 2 13q32.1 -1.3586 -2.9818 -1.6232
Table 2. List of 11 genes differentially expressed by 2- folds or greater 
DS Mean, Mean fluorescence intensities of DS subjects; Normal Mean, Mean fluorescence intensities of normal subjects; Pair Mean Ratio, Log2 DS Mean/
Normal Mean.
Fig. 3. Semi-quantitative RT-PCR analysis of normal vs. DS subjects.
RT-PCR analysis of COL3A1, GSTT1 and GAPDH was performed
in AF cells of 6 normal and 6 DS. GAPDH serves as an internal con-
trol. Lane 1-6: Normal subject, Lane 7-12: DS subject.
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DISCUSSION
The gene dosage hypothesis by extra chromosome 21 may
explain the neurological and other symptoms of DS. We ana-
lyzed the differential gene expression of AF cells of DS, alth-
ough it is not fully clear how our analysis using AF cells can
lead to the syndrome phenotype. Our analysis using AF cells
may not explain the direct pathogenesis of common DS phe-
notype, but could be important for prenatal diagnosis and
the study of DS fetus development.
According to the ‘‘gene dosage effect’’ hypothesis, the dif-
ferential regulation of chromosome 21 genes causes the DS
phenotype. Gazzolo et al. reported that S100B protein level
of AF were significantly higher (1.5 fold) in DS fetuses (14).
S100B gene is located on chromosome 21 and is calcium
binding protein originally isolated from the nervous system
(15). This gene is not only overexpressed in AF, but also life-
long overexpressed in DS (11). 
In the present study, we identified 11 differentially expressed
genes in AF cells in DS. GSTT1, the up-regulated gene, plays
a role for the intracellular binding, transport of many bio-mo-
lecular entities, and detoxification process. GSTT1 was not
detected in any fetal organs examined, but found in deciduas
(16). Moreover, this gene was absent in 38% of the population
(17), and we found this gene up-regulated in AF cells of DS by
approximately 4-folds in semi-quantitative RT-PCR analysis.
COL6A1, COL3A1 and OSF-2, three of the ten down-reg-
ulated genes, code for components of the extracellular matrix
(ECM). COL6A1 protein was reported to be down-regulated
in the brain of DS fetus (18) and to be expressed in the devel-
oping atrioventricular (AV) canal. Genetic variations of this
gene have been associated with DS AV defects in human gene-
tic studies (19). According to recently published data, expres-
sion changes of the ECM-related genes may also contribute
to cardiac defects (19) and abnormalities of brain in DS (20,
21). COL3A1 gene, which encodes chains of type III procol-
lagen, is important for the development of skin, the cardio-
vascular system and maintaining the normal physiological
functions of these organs (22). Superti-Furga et al. provided
the first description of a mutation of the COL3A1 gene in
type IV Ehlers-Danlos syndrome (EDS). Synthesis of type III
collagen is defective in type IV EDS (23). OSF-2, transcrip-
tion activation protein, might play a role in cell to cell com-
munication in bone, ECM turnover and switches cells into
the osteoblastic pathway (24). It is possible that abnormal
expression of OSF-2 may affect increased flexibility in joints
of DS patients. 
Beta amyloid precursor protein (APP), CuZn superoxide
dismutase (SOD1) and S100beta have been implicated in caus-
ing apoptosis thought to be responsible for neuronal loss in
DS (25). Little is known, however, about the changes of cas-
pases and their regulatory proteins in DS. Gulesserian et al.
reported that procaspase-3 and -8 were significantly decreased
in frontal cortex (26). Although we used AF cells in this study,
caspase-3 was down-regulated. BNIP1, Pro-apoptotic protein,
was also down-regulated. This gene interacts with BCL-2
family which is anti-apoptosis proteins (27).
According to the gene dosage hypothesis, some genes on
chromosome 21 would overexpress in DS. Previous study
showed that the genes located on chromosome 21 have been
found to be overexpressed in cells and tissues of DS (28). Our
data showed that the expression level of most genes located
on chromosome 21 (22/24 genes) did not change in the AF
cells of DS. Only two genes (COL6A1 and PRSS7) were dif-
ferentially expressed, especially for down regulation in the AF
cells of DS. Our microarray analysis determined the expres-
sions of 102 genes potentially important in DS and may pro-
vide the basis for a more systematic identification of biomark-
ers, thus leading to understanding of the developmental and
pathogenic study for fetal DS.
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